EUVIMEDEUVIMED entdecken
Crossref

Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor

Tomoki Koishikawa, Yukana Tomoda, Toshiaki Tsuchitani, Kunal Taskar, Kenta Yoshida, Jialin Mao, Tadayuki Takashima, Yurong Lai, Yuichi Sugiyama, Hiroyuki Kusuhara

Drug Metabolism and Disposition · 2025-06 · 53 (6) · 100087

DOI: 10.1016/j.dmd.2025.100087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025-06. Verfasst von Tomoki Koishikawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Organic Cation Transporter 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science London, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dolutegravir is a clinically confirmed inhibitor of organic cation transporter 2 (OCT2)/SLC22A2; however, its in vitro IC50 varies widely across studies. Using OCT2-expressing human embryonic kidney 293 cells, we investigated experimental conditions affecting IC50 determination. Based on clinical drug-drug interaction (DDI) data, an inhibition constant (Ki) of 0.0890 μM was estimated through pharmacokinetic (PK) modeling using both plasma concentration and urinary excretion profiles of metformin. In vitro, dolutegravir was found to be a noncompetitive inhibitor of OCT2. IC50 values increased with longer uptake times. A 2.9-fold difference was already observed between 1-minute and 5-minute uptake, and further extension to 30 minutes resulted in a 27-fold increase, attributable to the inhibition of both uptake and efflux processes. Preincubation of the cells with dolutegravir for 30 minutes additionally enhanced its inhibitory effect, resulting in a 5.8-fold decrease in IC50. Similar uptake time dependency was observed with other inhibitors (cimetidine and pyrimethamine). However, the extent of variability differed among metformin, N1-methylnicotinamide, atenolol, frovatriptan, and sumatriptan, likely reflecting differences in cellular kinetics. The lowest in vitro IC50 of dolutegravir for metformin uptake (0.126 μM), obtained under a 1-minute uptake and 30-minute preincubation condition, closely matched the estimated in vivo Ki. DDI predictions using in vitro IC50 values suggested repeated dolutegravir administration could raise the area under the curve of OCT substrates, such as atenolol, nadolol, and sulpiride beyond regulatory thresholds. In conclusion, we identified optimized in vitro conditions that yield IC50 values consistent with in vivo Ki estimates, offering valuable guidance for predicting OCT2-mediated DDIs. SIGNIFICANCE STATEMENT: This study identified experimental conditions affecting the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor. These findings offer valuable insights for improving in vitro to in vivo drug-drug interaction predictions and optimizing inhibition experiments for transporter-mediated drug-drug interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingOrganic Cation Transporter 2HumansOxazinesPiperazinesPyridonesHEK293 CellsMetforminInhibitory Concentration 50Drug InteractionsDolutegravir

Stichwörter der Autor:innen

Drug-drug interactionHalf-maximal inhibitory concentrationInhibition constantOrganic cation transporter 2Physiologically based pharmacokinetic

Substanzen

OxazinesPiperazinesPyridonesHeterocyclic Compounds, 3-RingOrganic Cation Transporter 2MetforminDolutegravirSLC22A2 protein, human

Autor:innen und Institutionen

  • Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo-ku, Tokyo, Japan.
  • Faculty of Pharmacy, Keio University, Minato-ku, Tokyo, Japan.
  • Drug Metabolism and Pharmacokinetic, GSK, Stevenage, United Kingdom.
  • Clinical Pharmacology, Genentech, Inc., South San Francisco, California.
  • Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California.
  • Laboratory for Safety Assessment & ADME, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, Shizuoka, Japan.

Förderung

  • Japan Society for the Promotion of Science London
  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Koishikawa, T., Tomoda, Y., Tsuchitani, T., Taskar, K., Yoshida, K., Mao, J., Takashima, T., Lai, Y., Sugiyama, Y., & Kusuhara, H. (2025). Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor. Drug Metabolism and Disposition, 53(6), 100087. https://doi.org/10.1016/j.dmd.2025.100087

Vancouver

Koishikawa T, Tomoda Y, Tsuchitani T, Taskar K, Yoshida K, Mao J, et al. Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor. Drug Metabolism and Disposition. 2025;53(6):100087. doi:10.1016/j.dmd.2025.100087

BibTeX
@article{Koishikawa2025,
  author = {Koishikawa, Tomoki and Tomoda, Yukana and Tsuchitani, Toshiaki and Taskar, Kunal and Yoshida, Kenta and Mao, Jialin and Takashima, Tadayuki and Lai, Yurong and Sugiyama, Yuichi and Kusuhara, Hiroyuki},
  title = {Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  volume = {53},
  number = {6},
  pages = {100087},
  doi = {10.1016/j.dmd.2025.100087}
}
Kostenlos starten →